Unsafe Drugs: Tamiflu Patients Need Monitoring

Health officials unveiled a new warning on the labeling of the influenza drug Tamiflu: patients taking the drug should be monitored for signs of abnormal behavior. The precaution comes after more than 100 reports of delirium, hallucinations, and other unusual psychiatric behavior were linked to children taking the drug.

FDA: Tamiflu patients need monitoring

The Food and Drug Administration said that a relationship between the drug and the unusual behavior had not been established and that the updated label merely is to "intended to mitigate a potential risk associated with Tamiflu." The previous FDA Tamiflu label warned that "seizure and confusion" had been seen in some patients. Tamiflu manufacturer Roche Holding AG responded that there was no evidence of the drug causing the rarely occurring adverse side effects.